Evaluating the Safety and Efficacy of the Maurora® DES in ICAS

Inclusion Criteria: 1. Age from 18 to 80 years; 2. Symptomatic intracranial atherosclerosis (Definition: Stroke or transient ischemic attack \[TIA\] associated with intracranial atherosclerosis within 90 days of enrollment); 3. A major intracranial artery (carotid artery, MCA stem \[M1\], vertebral artery, or basilar artery) with 70% to 99% stenosis on the angiography (According to WASID method); 4. The target lesion length ≤15 mm and the vessel diameter between 2.5mm and 5.0mm, distal vessel diameter \>1.5mm; 5. Only one stent planned for the target lesion; 6. A Modified Rankin Score of ≤ 3; 7. Patients understand the purpose and requirements of the study, and can make him/herself understood, and has provided informed consent. Exclusion Criteria: 1. Ischemic stroke within 2 weeks before the procedure; 2. Tandem extracranial or intracranial stenosis (70%-99%) of the target lesion; 3. Patients with stroke caused by perforating artery occlusion; 4. Severe calcification at target lesion; 5. Any history of brain parenchymal or other intracranial subarachnoid, subdural or extradural hemorrhage in the past 6 weeks; 6. History of stenting or angioplasty of an intracranial artery; 7. Intracranial tumor, aneurysm or intracranial arteriovenous malformation; 8. Intracranial artery stenosis caused by non-atherosclerotic lesions, including: moya-moya disease, vasculitis disease, herpes zoster, varicella-zoster or other viral vascular diseases, neurosyphilis, any other intracranial infections, radiation-induced vascular disease, fibromuscular dysplasia, sickle cell disease, neurofibromatosis, central nervous system benign vascular disease, post-partum vascular disease, suspected vasospasm, suspicious embolism recanalization; 9. Presence of any unequivocal cardiac source of embolism (e.g. atrial fibrillation); 10. Those who cannot tolerate general anesthesia due to insufficiency of cardiac or pulmonary function, not suitable for procedure; 11. Known allergy or contraindication to heparin, aspirin, ticlopidine, ticagrelor, sirolimus, anaesthetics and contrast agents; 12. Severe renal and hepatic insufficiency (ALTor AST \> 3x upper limit, creatinine \> 1.5x upper limit); 13. Major surgery within the past 30 days or planned within 90 days, or requiring simultaneous intervention to renal artery, iliac artery, and coronary artery; 14. Life expectancy \<12 months; 15. Pregnant or lactating women, or planning for pregnancy; 16. Participated in another investigational device or drug study within 30 days; 17. According to the judgement of the investigator, other situations that are not suitable for enrollment.